-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Exagen, Raises Price Target to $9

Benzinga·08/05/2026 12:08:41
Listen to the news
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.